Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

被引:630
作者
Karantanos, T. [1 ]
Corn, P. G. [1 ]
Thompson, T. C. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
castrate-resistant prostate cancer; ADT; alternative pathways; EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TRANSCRIPTIONAL ACTIVITY; SUPPRESSES TUMOR-GROWTH; BETA-CATENIN; IN-VIVO; GENE-EXPRESSION; SIGNALING AXIS; BREAST-CANCER; UP-REGULATION; SIPULEUCEL-T;
D O I
10.1038/onc.2013.206
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of <20 ng/dl. The recent discovery that AR signaling persists during systemic castration via intratumoral production of androgens led to the development of novel anti-androgen therapies including abiraterone acetate and enzalutamide. Although these agents effectively palliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable. An increased understanding of the mechanisms that underlie the pathogenesis of castrate resistance is therefore needed to develop novel therapeutic approaches for this disease. The aim of this review is to summarize the current literature on the biology and treatment of castrate-resistant prostate cancer.
引用
收藏
页码:5501 / 5511
页数:11
相关论文
共 156 条
[31]   AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo [J].
Faubert, Brandon ;
Boily, Gino ;
Izreig, Said ;
Griss, Takla ;
Samborska, Bozena ;
Dong, Zhifeng ;
Dupuy, Fanny ;
Chambers, Christopher ;
Fuerth, Benjamin J. ;
Viollet, Benoit ;
Mamer, Orval A. ;
Avizonis, Daina ;
DeBerardinis, Ralph J. ;
Siegel, Peter M. ;
Jones, Russell G. .
CELL METABOLISM, 2013, 17 (01) :113-124
[32]   Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [J].
Fizazi, Karim ;
Scher, Howard I. ;
Molina, Arturo ;
Logothetis, Christopher J. ;
Chi, Kim N. ;
Jones, Robert J. ;
Staffurth, John N. ;
North, Scott ;
Vogelzang, Nicholas J. ;
Saad, Fred ;
Mainwaring, Paul ;
Harland, Stephen ;
Goodman, Oscar B., Jr. ;
Sternberg, Cora N. ;
Li, Jin Hui ;
Kheoh, Thian ;
Haqq, Christopher M. ;
de Bono, Johann S. .
LANCET ONCOLOGY, 2012, 13 (10) :983-992
[33]   Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1;: Pten mice [J].
Gao, Hui ;
Ouyang, Xuesong ;
Banach-Petrosky, Whitney A. ;
Shen, Michael M. ;
Abate-Shen, Cory .
CANCER RESEARCH, 2006, 66 (16) :7929-7933
[34]  
Gregory CW, 2001, CANCER RES, V61, P4315
[35]   Regulation of androgen receptor activity by tyrosine phosphorylation [J].
Guo, Zhiyong ;
Dai, Bojie ;
Jiang, Tianyun ;
Xu, Kexin ;
Xie, Yingqiu ;
Kim, Oekyung ;
Nesheiwat, Issa ;
Kong, Xiangtian ;
Melamed, Jonathan ;
Handratta, Venkatesh D. ;
Njar, Vincent C. O. ;
Brodie, Angela M. H. ;
Yu, Li-Rong ;
Veenstra, Timothy D. ;
Chen, Hegang ;
Qiu, Yun .
CANCER CELL, 2006, 10 (04) :309-319
[36]   Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis [J].
Gurel, Bora ;
Iwata, Tsuyoshi ;
Koh, Cheryl M. ;
Jenkins, Robert B. ;
Lan, Fusheng ;
Van Dang, Chi ;
Hicks, Jessica L. ;
Morgan, James ;
Cornish, Toby C. ;
Sutcliffe, Siobhan ;
Isaacs, William B. ;
Luo, Jun ;
De Marzo, Angelo M. .
MODERN PATHOLOGY, 2008, 21 (09) :1156-1167
[37]   Androgen receptor levels are upregulated by Akt in prostate cancer [J].
Ha, Susan ;
Ruoff, Rachel ;
Kahoud, Nicole ;
Franke, Thomas F. ;
Logan, Susan K. .
ENDOCRINE-RELATED CANCER, 2011, 18 (02) :245-255
[38]   Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide [J].
Haapala, K ;
Hyytinen, ER ;
Roiha, M ;
Laurila, M ;
Rantala, I ;
Helin, HJ ;
Koivisto, PA .
LABORATORY INVESTIGATION, 2001, 81 (12) :1647-1651
[39]   Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [J].
Harris, William P. ;
Mostaghel, Elahe A. ;
Nelson, Peter S. ;
Montgomery, Bruce .
NATURE CLINICAL PRACTICE UROLOGY, 2009, 6 (02) :76-85
[40]   Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells [J].
Heidegger, Isabel ;
Ofer, Philipp ;
Doppler, Wolfgang ;
Rotter, Varda ;
Klocker, Helmut ;
Massoner, Petra .
ENDOCRINOLOGY, 2012, 153 (10) :4633-4643